Pharmacoeconomic review report: Ixekizumab (Taltz)
Ixekizumab (Taltz) is a humanized anti-interleukin (IL)-17A monoclonal antibody indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systematic therapy or phototherapy. The manufacturer is requesting listing of ixekizumab for adult patients in...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
September 2017, 2017
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references